Nucleome Therapeutics’ Post

#RNA: the next era in therapeutic development The rapid pace of innovation in the #analyticaltools space is playing a crucial role in driving the gene and #celltherapy field toward an industrialized, commercially successful future. Recently published content in this space includes an #eBook that establishes the basics of RNA therapeutic production and development, explores in-depth the significant challenges that still exist, and offers a potential roadmap to success in this exciting emerging field. https://buff.ly/3QnbYDN This is just one of the resources available on our Droplet Digital PCR (#ddPCR) Hub. The #hub explores the specific utility, considerations, and advantages of utilizing ddPCR from the early stages of product and process development through to clinical and commercial manufacture of #viralvectors and RNA. Once you’ve read your first piece of content, all the rest is available to you open access. View the hub below: https://buff.ly/3QlkpzG

Automation of well plate and culture tube processes are now well established for microbial and all types of mammalian + insect cell culture systems. Automation-driven capacity gains and culture-cost reductions once thought limited to mainstream biologics (transient + stable CHO fed-batch) are now possible with technically challenging AAV gene therapy, CHO perfusion, CAR-T applications and large volume cultures (300ml-1,800ml)… if you know what you’re doing. Not all scaling factors are created equal: matched kLa, consistent energy dissipation rates (shear) and controlling evaporative losses are important (among other factors) – but each application may have different priorities. Understand what your cultivation priorities are and how to manipulate your conditions for consistency – join us at our Boston symposium October 23rd. We have great keynote speakers and will also cover scale-up fundamentals so you may identify what your priorities are and how to keep them consistent as you scale your specific cultures. We will further deep-dive into advanced roboticized well plates and closures for all types cultivations and look at key steps to consider when automating your process. #automation, #bostonbiotech, #cellculture, #processdevelopment https://lnkd.in/g8du37Vk

🚀🔬🌱 **Unveiling the Future: Top 10 Biotech Industry Trends & Innovations** From groundbreaking gene therapies to sustainable bio-manufacturing, the world of biotech is changing faster than ever! Are you excited to explore the latest innovations shaping healthcare and beyond? 🔍Take a look at this post to uncover the trends driving the biotech revolution! 💡 Join the conversation and share which innovations you think will make the biggest impact or which ones have already amazed you! #sharing_is_caring #BioTech #Innovation #HealthcareTrends #FutureOfBiotech #Genetherapy #FutureofMedicine

This week our CEO, Leslie J Williams, will be participating in the RNA Leaders USA Congress in San Diego, CA.    On Thursday, Leslie will present on tRNAs, molecular interpreters that translate the genetic code into proteins, and how they can be engineered to treat genetically defined diseases. Later that day, she will also join a panel on the future of RNA therapeutics alongside biotech leaders Trevor Hallam, Rachel Groppo, Brendan Frey, and moderator Michael Hodges, where they’ll discuss promising approaches that are being fast-tracked to the clinic.    We look forward to sharing our insights and engaging with other stakeholders on the latest #RNA developments! Learn more: https://bit.ly/4cswWcw    #RNALeadersUSA #biotech #RNAtherapeutics #RNALeaders 

Spur Therapeutics CEO Michael Parini sat with BiotechTV’s Amy Brown for an insightful discussion about Spur’s new chapter and how it is optimizing every component of its product candidates, improving genetic expression and targeted delivery to realize outsized clinical results. Watch the interview below to learn more about Spur and its plan to take its gene therapy candidate for #Gaucher disease into Phase 3. 🚀

🌟 Exciting News Alert! 🌟 We're thrilled to share the publication of our LATEST SCIENTIFIC ARTICLE:  "A Zebrafish-Based Platform for High-Throughput Epilepsy Modeling and Drug Screening in F0" in the International Journal of Molecular Sciences (MDPI). Here, we present an integrative approach for rapid and high-throughput generation of knock-out (KO) zebrafish models for target identification/validation in epilepsy and screening of antiepileptic drugs (AEDs). By co-inactivation of the target gene and an endogenous reporter locus we developed a method to efficiently select mutant animals and to test the therapeutic effect of compounds. Read the full abstract here: [https://bit.ly/3IuTnRU] Join us as we continue to push the boundaries of scientific innovation and promote zebrafish use in cutting-edge research. Let's advance together towards a brighter and healthier future! #ZebrafishResearch #DrugDiscovery #EpilepsyModeling #ScientificInnovation

🔝Massive Scale Knowledge Graph is ready! 🔝 QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery! Press release of today 👍 https://lnkd.in/gzEJSa4k #drugdiscovery #pharma #neo4j #datascience #ai #bioinformatics

Recently, my colleague @Philip Ramsey gave a noteworthy talk on statistics in #CMC.   It’s a promising time to be a part of cell and gene therapies, but on the statistical side of #CMC one big problem comes up with some frequency: System Complexity. As Philip Ramsey and Patricia McNeill of Lundbeck note, some treatments can involve 10-20+ critical quality attributes, each influenced by numerous interconnected process parameters. So how should statistical methods handle complexity in these systems? 💬 Phil offers the following: "You have to experiment in ways that capture interactive behavior. It's all about prediction and how well your models can interpolate over the design region." At @Predictum Inc., we address these challenges with our #SVEM methodology, a machine learning approach that ensures accurate predictive modeling. Check out #SVEM in the recording above. We also have the full webinar on our site. It’s free. No email signup needed. You might be surprised how quickly #SVEM will make a difference. 📺 Watch the full webinar at predictum.com: https://bit.ly/4atDEOM #JMP #processdevelopment #processimprovement #drugdevelopment #pharmaceuticals

The methodology beneath this particular application is known as #SVEM, a machine learning method for small sets of data (as little as 20 or 30 observations). In this post (https://lnkd.in/gx9i2Acm) it's talked about in terms of CMC/pharmaceuticals. But the same methodology has been applied in other areas from asphalt to advanced chemical formulations. It's a game changer and I encourage you to look into it (https://lnkd.in/gpcFccJt).

Want to explore #allogeneic #celltherapy manufacturing, donor comparability, screening and more? Our COO, Loren Wagner, speaks to Cell & Gene about how Poseida is solving for the future. Watch the replay: https://lnkd.in/d_ndrjKK     #CapacitytoCure #CART